CheckMate 9ER: Efficacy of First-line Nivolumab + Cabozantinib vs Sunitinib in Advanced/Metastatic RCC by Baseline Patient Characteristics

June 4-8, 2021; Online at https://conferences.asco.org/am
Exploratory analyses of the CheckMate 9ER trial suggested PFS benefit with nivolumab + cabozantinib vs sunitinib across assessed subgroups defined by baseline disease characteristics.
Format: Microsoft PowerPoint (.ppt)
File Size: 228 KB
Released: June 6, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on best practices in classifying prostate cancer and using ADT

Daniel W. Lin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with mHSPC.

Alicia K. Morgans, MD, MPH Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue